HeartBeam, Inc.
No SEC Form 4 filings for $BEAT in the last 30 days.
See all $BEAT insider activity →U.S. stocks rose midday, with the Dow up 0.20% and NASDAQ up 0.84%. ISM services PMI fell to 54.9 in September. Columbus Acquisition (SAIQ) surged 286% post-SPAC merger, Vaxcyte (PCVX) up 40% on trial results, and HeartBeam (BEAT) up 70% after FDA designation. Camping World (CWH) down 10% on EBITDA guidance cut.
HeartBeam (BEAT) received FDA Breakthrough Device Designation for its HeartBeam System, which assesses potential heart attacks at home. The system uses 3D ECG technology to enable remote diagnosis. The designation accelerates development and regulatory review. BEAT stock rose 3.72% on October 2, 2026, and was up 97.42% in pre-market trading.
HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 14, 2026, HeartBeam, Inc. (the “Company”), entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Titan Partners Securities LLC, as sales agent, pursuant to which the Company may
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BEAT (HeartBeam, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent BEAT coverage spans corporate actions, financial news and regulation.
Breakthrough designation fuels rally.
Positive regulatory news likely to lift BEAT shares as investors price in faster FDA review and potential market expansion.
The filing discloses a new equity issuance mechanism (ATM), which can increase dilution over time and may pressure the stock near-term depending on expected use of proceeds.
Earnings miss plus only partial offset from lower full-year cash outflow guidance is likely to keep near-term sentiment pressured.
The filing is primarily governance housekeeping. The only potentially market-relevant item is that the equity incentive plan share increase proposal was not approved.
AlphAI scores every news story that mentions BEAT with an AI model for sentiment and relevance, and aggregates insider trades from HeartBeam, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stocks rose midday, with the Dow up 0.20% and NASDAQ up 0.84%. ISM services PMI fell to 54.9 in September. Columbus Acquisition (SAIQ) surged 286% post-SPAC merger, Vaxcyte (PCVX) up 40% on trial results, and HeartBeam (BEAT) up 70% after FDA designation. Camping World (CWH) down 10% on EBITDA guidance cut.
2 min readHeartBeam (BEAT) received FDA Breakthrough Device Designation for its HeartBeam System, which assesses potential heart attacks at home. The system uses 3D ECG technology to enable remote diagnosis. The designation accelerates development and regulatory review. BEAT stock rose 3.72% on October 2, 2026, and was up 97.42% in pre-market trading.
2 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 14, 2026, HeartBeam, Inc. (the “Company”), entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Titan Partners Securities LLC, as sales agent, pursuant to which the Company may
3 min readHeartbeam Inc shares fell 1.7% after hours to $0.58 after the company reported Q2 2026 results. Net loss was $0.10 per share versus a $0.09 estimate, with operating expenses of $5.1M. Heartbeam lowered full-year 2026 cash outflow guidance and said ALIGN-ACS pilot enrollment was completed early.
4 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On July 31, 2026, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast. As of the close of business on June 5, 2026, the record date for the Annual M
2 min readHeartBeam Inc. (BEAT) said the U.S. Patent Office allowed a new patent covering acoustic sensing and thoracic impedance measurement for its cable-free ECG device. The company says the device can act as a digital stethoscope and monitor chest fluid buildup for heart failure management. BEAT shares were about $0.50, down 11.91%, near a 52-week low.
2 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001779372 0001779372 2026-06-18 2026-06-18 0001779372 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001779372 us-gaap:WarrantMember 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
2 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 ea029531801ex10-2.htm TRANSACTION BONUS AGREEMENT, DATED JUNE 15, 2026, BY AND BETWEEN HEARTBEAM, INC. AND BRANISLAV VAJDIC Exhibit 10.2 B Vajdic Performance Award 6.2026 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT
3 min readHeartBeam (NASDAQ: BEAT), a medical technology company, will host a conference call on May 13, 2026, to discuss its first-quarter results for 2026. The call will also provide updates on key growth initiatives, including its commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs. HeartBeam is focused on cardiac care innovation with its 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025.
4 min readHeartBeam President Robert Paul Eno purchased 12,500 shares of common stock at $0.80 per share on April 16, 2026, in connection with the company's 12.5 million-share public offering. This transaction increased his direct holdings to 36,742 shares, which includes 23,333 vested RSUs. The offering was priced on April 14, 2026, and closed on the same day as Eno's purchase.
2 min read